Sinopharm Group Co., Ltd. (02617): The first patient in the phase II clinical trial of the combination of Kangfusheng biological ketani (cardunilum, PD-1/CTLA-4) / Yidafang (Yivosi, PD-1/VEGF) with Tengmino received medication.

Zhtng Cijng APP News, Pharmaron Health-B (02617) announced that the company's core product Tinengotinib (TT-00420) was used in combination with ConFab Biotech (Cayman) Limited's Opdivo (Nivolumab, PD-1/CTLA-4) / Avastin (Bevacizumab, PD-1/VEGF) in an open-label, multicenter phase II clinical study for the treatment of advanced hepatocellular carcinoma (HCC), and the first patient was recently dosed.